

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

## EQA round: KD2/19 - Glycated Haemoglobin

Dead line: 31.05.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability						Traceability															
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(220) Haemoglobin A1c</b>					91																91	84	92%
— Samples and groups —	[mmol/mol]																						
<b>Sample A</b>		57,9	3,2	5,6	91									RV	58,1	0,90	14%	49,9	66,3	91	89	98%	
(14) Bio-Rad		57,5	4,0	7,0	24	0															24		
(25) TOSOH		58,3	2,3	4,0	29	0															29		
(60) Roche		60,0	3,8	6,3	8	0															8		
(150) Arkray		55,8	2,5	4,4	22	0															22		
Other					8	0															8		
<b>Sample B</b>		42,4	2,6	6,2	91									RV	42,2	0,70	14%	36,2	48,2	91	85	93%	
(14) Bio-Rad		42,8	3,1	7,3	24	0															24		
(25) TOSOH		42,7	1,9	4,4	29	0															29		
(60) Roche		43,8	2,6	6,0	8	0															8		
(150) Arkray		40,5	1,9	4,7	22	0															22		
Other					8	0															8		
															1x 1, 2x 46, 1x 49, 1x 58, 1x 149, 1x 165, 1x 196								

st\_kn\_np

End of report

Printed: 08.06.2019